FDA Advisory Panel to Review Restrictions on Seven Compounded Peptides

An FDA advisory panel is scheduled to convene on July 23–24 to determine whether to ease restrictions on seven specific peptides. If approved, these substances could be legally produced and distributed by compounding pharmacies for patient use. The substances under review include TB-500, BPC-157, Semax, Epitalon, Emideltide, KPV, and MOTs-C.

These peptides were previously restricted in 2023, effectively prohibiting their production by compounding pharmacies due to safety concerns. Current regulatory debate centers on whether these compounds meet established scientific standards for human efficacy and safety. Critics emphasize that existing data is largely derived from animal studies, leaving significant gaps in human pharmacology and toxicology profiles.

Proponents argue that broader access could facilitate necessary clinical evaluation and provide therapeutic options for conditions such as obesity, wound healing, and inflammatory diseases. Conversely, medical experts warn that the lack of systematic human trials poses potential risks to public health. Any recommendation from the advisory panel remains subject to final approval by FDA administrators.